13C20,15N10-Cyclic di-GMP (sodium)

O=[13C]1[15NH][13C]([15NH2])=[15N][13C]2=[13C]1[15N]=[13CH][15N]2[13C@H](O[13C@@]([13C@@]3([H])OP(O[13CH2][13C@]([13C@@]4([H])OP5(O[Na])=O)(O[13C@@H]([15N]6[13C]([15N]=[13C]([15NH2])[15NH][13C]7=O)=[13C]7[15N]=[13CH]6)[13C@@H]4O)[H])(O[Na])=O)([13CH2]O5)[H])[13C@@H]3O

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Karaolis DK, et al. 3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun. 2005 Apr 1;329 (1) :40-5. |[3]Steinberger O, et al. Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3',5'-cyclic diguanylic acid. FEBS Lett. 1999 Feb 5;444 (1) :125-9. |[4]Wang Z, et al. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother. 2015 Aug;64 (8) :1057-66. |[5]Jenal U, et al. Cyclic di-GMP: second messenger extraordinaire. Nat Rev Microbiol. 2017 May;15 (5) :271-284.